Spoken Alpha
CLRB
Cellectar Biosciences, Inc.
Overview
Cellectar Biosciences, Inc is a Healthcare company operating in Biotechnology with a $11.6M market cap.
CLRB missed consensus EPS by 0.0% in Q2 FY2026, reported Aug 12, 2026.
12 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from SEC 10-K filing, 2026-10-04.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q2 FY2026Earnings2026-08-133 Q&A exchanges
- Q1 FY2026Earnings2026-05-143 Q&A exchanges
- Q4 FY2025Earnings2026-03-048 Q&A exchanges
- Q3 FY2025Earnings2025-11-1313 Q&A exchanges
- Q2 FY2025Earnings2025-08-143 Q&A exchanges
- Q1 FY2025Earnings2025-05-134 Q&A exchanges
- Q4 FY2024Earnings2025-03-1312 Q&A exchanges
- Q3 FY2024Earnings2024-11-183 Q&A exchanges
- Q2 FY2024Earnings2024-08-1318 Q&A exchanges
- Q1 FY2024Earnings2024-05-145 Q&A exchanges
- Q4 FY2023Earnings2024-03-279 Q&A exchanges
- Q3 FY2023Earnings2023-11-0214 Q&A exchanges
History
Earnings history
- Q2 FY20262026-08-12EPS$-0.57 vs $-0.55-3.6%Rev$0 vs ——EODHD
- Q1 FY20262026-05-13EPS$-1.33 vs $-1.88+29.3%Rev$0 vs ——EODHD
- Q4 FY20252026-03-03EPS$-0.53 vs $-1.23+56.7%Rev$0 vs ——EODHD
- Q3 FY20252025-11-12EPS$-1.41 vs $-2.53+44.3%Rev$0 vs ——EODHD
- Q2 FY20252025-08-13EPS$-3.39 vs $-3.70+8.4%Rev$0 vs ——EODHD
- Q1 FY20252025-05-12EPS$-4.20 vs $-4.90+14.3%Rev$0 vs ——EODHD
- Q4 FY20242025-03-24EPS$-0.01 vs $-0.35+97.2%Rev$309.0K vs ——EODHD
- Q3 FY20242024-11-17EPS$-11.10 vs $-11.20+0.9%Rev$0 vs ——EODHD
- Q2 FY20242024-08-12EPS$-0.32 vs $-0.30-6.7%Rev$0 vs ——EODHD
- Q1 FY20242024-05-13EPS$-22.20 vs $-16.90-31.4%Rev$330.4K vs ——EODHD
- Q4 FY20232024-03-26EPS$-0.61 vs $-0.57-7.0%Rev$330.4K vs ——EODHD
- Q3 FY20232023-11-12EPS$-24.84 vs $-13.35-86.1%Rev$0 vs ——EODHD
- Q2 FY20232023-08-13EPS$-21.90 vs $-19.95-9.8%Rev$0 vs ——EODHD
- Q1 FY20232023-05-03EPS$-22.80 vs $-26.03+12.4%Rev$0 vs ——EODHD
- Q4 FY20222023-03-08EPS$-0.55 vs $-1.07+48.6%Rev$0 vs ——EODHD
- Q3 FY20222022-11-02EPS$-38.40 vs $-37.70-1.9%Rev$0 vs ——EODHD
- Q2 FY20222022-08-04EPS$-36.60 vs $-31.05-17.9%Rev$0 vs ——EODHD
- Q1 FY20222022-05-09EPS$-30.00 vs $-30.000.0%Rev$0 vs ——EODHD
- Q4 FY20212022-03-20EPS$-0.90 vs $-1.02+11.8%Rev$0 vs ——EODHD
- Q3 FY20212021-11-07EPS$-30.00 vs $-33.00+9.1%Rev$0 vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-12 | $-0.57 | $-0.55 | -3.6% | $0 | — | — | EODHD |
| Q1 FY2026 | 2026-05-13 | $-1.33 | $-1.88 | +29.3% | $0 | — | — | EODHD |
| Q4 FY2025 | 2026-03-03 | $-0.53 | $-1.23 | +56.7% | $0 | — | — | EODHD |
| Q3 FY2025 | 2025-11-12 | $-1.41 | $-2.53 | +44.3% | $0 | — | — | EODHD |
| Q2 FY2025 | 2025-08-13 | $-3.39 | $-3.70 | +8.4% | $0 | — | — | EODHD |
| Q1 FY2025 | 2025-05-12 | $-4.20 | $-4.90 | +14.3% | $0 | — | — | EODHD |
| Q4 FY2024 | 2025-03-24 | $-0.01 | $-0.35 | +97.2% | $309.0K | — | — | EODHD |
| Q3 FY2024 | 2024-11-17 | $-11.10 | $-11.20 | +0.9% | $0 | — | — | EODHD |
| Q2 FY2024 | 2024-08-12 | $-0.32 | $-0.30 | -6.7% | $0 | — | — | EODHD |
| Q1 FY2024 | 2024-05-13 | $-22.20 | $-16.90 | -31.4% | $330.4K | — | — | EODHD |
| Q4 FY2023 | 2024-03-26 | $-0.61 | $-0.57 | -7.0% | $330.4K | — | — | EODHD |
| Q3 FY2023 | 2023-11-12 | $-24.84 | $-13.35 | -86.1% | $0 | — | — | EODHD |
| Q2 FY2023 | 2023-08-13 | $-21.90 | $-19.95 | -9.8% | $0 | — | — | EODHD |
| Q1 FY2023 | 2023-05-03 | $-22.80 | $-26.03 | +12.4% | $0 | — | — | EODHD |
| Q4 FY2022 | 2023-03-08 | $-0.55 | $-1.07 | +48.6% | $0 | — | — | EODHD |
| Q3 FY2022 | 2022-11-02 | $-38.40 | $-37.70 | -1.9% | $0 | — | — | EODHD |
| Q2 FY2022 | 2022-08-04 | $-36.60 | $-31.05 | -17.9% | $0 | — | — | EODHD |
| Q1 FY2022 | 2022-05-09 | $-30.00 | $-30.00 | 0.0% | $0 | — | — | EODHD |
| Q4 FY2021 | 2022-03-20 | $-0.90 | $-1.02 | +11.8% | $0 | — | — | EODHD |
| Q3 FY2021 | 2021-11-07 | $-30.00 | $-33.00 | +9.1% | $0 | — | — | EODHD |
Source: EODHD. CLRB reported actuals as published; sparse fields render as —.
Top executives
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for CLRB.
$ curl https://api.spokenalpha.com/v1/companies/CLRBFAQ
Frequently asked about CLRB
Where can I find Cellectar Biosciences, Inc.'s (CLRB) earnings call transcripts?
Spoken Alpha indexes CLRB's earnings call transcripts at https://spokenalpha.com/companies/CLRB. Each call links to attributed speakers and parsed analyst Q&A. Cellectar Biosciences, Inc.'s own investor relations page is at https://www.cellectar.com/investors.
When was Cellectar Biosciences, Inc.'s most recent earnings call?
Cellectar Biosciences, Inc. (CLRB) held its most recent earnings call on 2026-08-13, covering fiscal Q2 2026.
What sector is CLRB in?
Cellectar Biosciences, Inc. (CLRB) operates in the Healthcare sector (Biotechnology industry).